

HB 695 -- Emerging Issues in Cancer Medication

Sponsor: Scharnhorst

This bill prohibits a health benefit plan that provides coverage for cancer chemotherapy treatment from charging a higher co-payment, deductible, or coinsurance amount to a patient for a prescribed orally administered anticancer medication than the plan charges for an intravenously administered or injected cancer medication. A health insurance carrier cannot comply with this requirement by increasing the co-payment, deductible, or coinsurance amount for an intravenously administered or injected cancer medication covered under the plan.

Certain supplemental insurance policies are exempt from the provisions of the bill.